Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Operations

v3.19.1
Consolidated Statements of Operations - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Operating Expenses:    
Research and development $ 9,067 $ 1,068
Selling, general and administrative 12,487 134,502
Loss on impairment 228,515 0
Total operating expenses 250,069 135,570
Loss from Operations (250,069) (135,570)
Other income (expense)    
Interest expense/income (9,117) (8,602)
Total Other Income (Expense) (9,117) (8,602)
Income (loss) before minority interest and provision for income taxes (259,186) (144,172)
Provision for income taxes 0 0
Net loss $ (259,186) $ (144,172)
Weighted average shares outstanding    
Basic 50,240 16,769
Diluted 50,240 16,769
Net income (loss) per share    
Basic $ (5.16) $ (8.60)
Diluted $ (5.16) $ (8.60)